Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDS1 Antibody - N-terminal region | Login | MDS1 Antibody - N-terminal region | ||||||||||||||||
|
||||||||||||||||||
| PRDX1 Antibody | Login | PRDX1 Antibody | ||||||||||||||||
|
||||||||||||||||||
| PARK2 Antibody | Login | PARK2 Antibody | ||||||||||||||||
|
||||||||||||||||||
| PCNA Antibody | Login | PCNA Antibody | ||||||||||||||||
|
||||||||||||||||||
| BPIFA1 Antibody - middle region | Login | BPIFA1 Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| PDGFRA Antibody (Phospho-Tyr762) | Login | PDGFRA Antibody (Phospho-Tyr762) | ||||||||||||||||
|
||||||||||||||||||
| PDGFRA Antibody (Phospho-Tyr754) | Login | PDGFRA Antibody (Phospho-Tyr754) | ||||||||||||||||
|
||||||||||||||||||
| PDGFRB Antibody (Phospho-Tyr751) | Login | PDGFRB Antibody (Phospho-Tyr751) | ||||||||||||||||
|
||||||||||||||||||
| PDGFRB Antibody (Phospho-Tyr740) | Login | PDGFRB Antibody (Phospho-Tyr740) | ||||||||||||||||
|
||||||||||||||||||
| PDGFRB Antibody (Phospho-Tyr1021) | Login | PDGFRB Antibody (Phospho-Tyr1021) | ||||||||||||||||
|
||||||||||||||||||
| PDGFRB Antibody | Login | PDGFRB Antibody | ||||||||||||||||
|
||||||||||||||||||
| PDGFRB Antibody (Phospho-Tyr771) | Login | PDGFRB Antibody (Phospho-Tyr771) | ||||||||||||||||
|
||||||||||||||||||
| PDPK1 Antibody (Phospho-Tyr9) | Login | PDPK1 Antibody (Phospho-Tyr9) | ||||||||||||||||
|
||||||||||||||||||
| PGR Antibody | Login | PGR Antibody | ||||||||||||||||
|
||||||||||||||||||
| PIK3C2G Antibody - N-terminal region | Login | PIK3C2G Antibody - N-terminal region | ||||||||||||||||
|
||||||||||||||||||
| PIK3CA Antibody - middle region | Login | PIK3CA Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| PIM1 Antibody (Phospho-Tyr309) | Login | PIM1 Antibody (Phospho-Tyr309) | ||||||||||||||||
|
||||||||||||||||||
| PIK3CD Antibody - N-terminal region | Login | PIK3CD Antibody - N-terminal region | ||||||||||||||||
|
||||||||||||||||||
| PIK3R1 Antibody (Phospho-Tyr467/199) | Login | PIK3R1 Antibody (Phospho-Tyr467/199) | ||||||||||||||||
|
||||||||||||||||||
| PIK3R1 Antibody (Phospho-Tyr607) | Login | PIK3R1 Antibody (Phospho-Tyr607) | ||||||||||||||||
|
||||||||||||||||||
| PIK3R1 Antibody - middle region | Login | PIK3R1 Antibody - middle region | ||||||||||||||||
|
||||||||||||||||||
| PIK3R1 Antibody | Login | PIK3R1 Antibody | ||||||||||||||||
|
||||||||||||||||||
| PIK3R2 Antibody | Login | PIK3R2 Antibody | ||||||||||||||||
|
||||||||||||||||||
| PIK3R2 Antibody (Phospho-Tyr464) | Login | PIK3R2 Antibody (Phospho-Tyr464) | ||||||||||||||||
|
||||||||||||||||||
| PLCG1 Antibody (Phospho-Tyr783) | Login | PLCG1 Antibody (Phospho-Tyr783) | ||||||||||||||||
|
||||||||||||||||||


